AbCellera Biologics Inc.

News & Events

Press Releases

In The Media

1. AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

   Business Wire MAY 30, 2025 1:00 PM EDT
   ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being dev...
   READ ARTICLE

2. AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

   Business Wire MAY 14, 2025 5:00 PM EDT
   AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 Ab...
   READ ARTICLE

3. AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

   Business Wire MAY 12, 2025 3:30 PM EDT
   The Federal Circuit rejects Bruker Cellular’s invalidity challenge to AbCellera’s p...
   READ ARTICLE

4. AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

   Business Wire MAY 9, 2025 7:30 PM EDT
   ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for...
   READ ARTICLE

5. AbCellera Reports Q1 2025 Business Results

   Business Wire MAY 8, 2025 4:05 PM EDT
   AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All fin...
   READ ARTICLE

6. AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

   Business Wire APR 29, 2025 3:00 PM EDT
   Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor a...
   READ ARTICLE

7. AbCellera to Participate at Upcoming Investor Conferences in May and June

   Business Wire APR 8, 2025 4:05 PM EDT
   AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following inv...
   READ ARTICLE

8. AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

   Business Wire APR 3, 2025 4:05 PM EDT
   AbCellera (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, Ma...
   READ ARTICLE

9. AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

   Business Wire MAR 25, 2025 4:30 PM EDT
   AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclini...
   READ ARTICLE

10. AbCellera Reports Full Year 2024 Business Results

    Business Wire FEB 27, 2025 4:05 PM EST
    AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial ...
    READ ARTICLE